TESARO Announces Fourth Quarter and Year-End 2012 Operating Results

[at noodls] – Niraparib to be Advanced in a Phase 3 Pivotal Trial for Ovarian Cancer Enrollment Continues in the Global Registration Program for Rolapitant Achieved Third Dose-level in a Phase 1/2 Clinical Trial of … more

View todays social media effects on TSRO

View the latest stocks trending across Twitter. Click to view dashboard

See who TESARO is hiring next, click here to view